HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide

Abstract : Temozolomide (TMZ) is the main chemotherapeutic agent used for treating newly diagnosed Glioblas-toma Multiforme (GBM), the most frequent malignant brain tumors in adults. This alkylating agent induces DNA double strand breaks (DSBs) which in turn lead to apoptosis by activating the Bcl-2 controlled mitochondrial pathway. However, GBM invariably recur as tumors become resistant to TMZ. We investigated the implication of EGFR ligands in this resistance and we found that the pro Heparin Binding Epidermal Growth Factor (proHB-EGF) expression is linked to the early response to TMZ in human glioma cell lines. However, HB-EGF does not affect apoptosis per se although its expression is associated with the degradation of Mcl-1. HB-EGF is implicated in DSBs repair as silencing of HB-EGF increased γH2AX foci half-life as well as USP9X expression, two features that could be linked to the observed effect on Mcl-1. Our data demonstrate a new role for HB-EGF in TMZ treated cell lines.
Document type :
Journal articles
Complete list of metadatas

Cited literature [35 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01813093
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, June 12, 2018 - 8:09:47 AM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Quentin Séry, Marion Rabé, Lisa Oliver, François Vallette, Catherine Gratas. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. Biochemical and Biophysical Research Communications, Elsevier, 2017, 493 (4), pp.1377 - 1383. ⟨10.1016/j.bbrc.2017.09.162⟩. ⟨inserm-01813093⟩

Share

Metrics

Record views

79